REG - ValiRx PLC - Posting of Circular and Notice of General Meeting

ValiRxAnnouncement

10/12/2024 15:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241210:nRSJ5605Pa&default-theme=true

RNS Number : 5605P  ValiRx PLC  10 December 2024

ValiRx plc

 

("ValiRx" or the "Company")

 

Posting of Circular and Notice of General Meeting

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, announces that, further to
the announcement made on 9 December 2024, a circular (the "Circular"),
including the Notice of General Meeting and a Form of Proxy will be posted
today.

 

The General Meeting will be held at the offices of Fieldfisher LLP, Riverbank
House, 2 Swan Lane, London, EC4R 3TT at 11 a.m. on 30 December 2024.

 

A copy of the Circular will shortly be available for the Company's website at
https://www.valirx.com/aim-rule-26 (https://www.valirx.com/aim-rule-26) .

 

Capitalised terms used in this announcement shall, unless otherwise defined,
have the same meanings as set out in the Company's announcement of 9 December
2024.

 

                                                                                2024

 Announcement of the Fundraising                                                9 December

 Date of publication and posting of this Circular & the Form of Proxy           10 December

 Latest time and date for receipt of proxy forms                                11.00 a.m. on 24 December

 General Meeting                                                                30 December

 Announcement of the results of the General Meeting                             30 December

 Admission and dealings in the New Ordinary Shares expected to commence on AIM  8.00 a.m. on or around 31 December

 Expected date for CREST accounts to be credited for New Ordinary Shares to be  31 December
 held in uncertificated form

 Despatch of definitive share certificates in respect of the New Ordinary       by 14 January 2025
 Shares to be held in certificated form, if applicable

 

Notes:

 

1. Each of the times and dates above are indicative only and if any of the
details contained in the timetable above should change, the revised times and
dates will be notified to Shareholders by means of an announcement through a
Regulatory Information Service.

2. All of the above times refer to London time unless otherwise stated.

3. All events listed in the above timetable related to the Admission, the
Placing, the Broker Offer and the Subscription are conditional on the passing
at the General Meeting of the Resolutions to provide the relevant authorities.

 

 

*** ENDS ***

 

 

 

For more information, please contact:

 ValiRx plc                                        Tel: +44 (0) 2476 796496

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston (mailto:Mark.Eccleston@valirx.com) @valirx.com

                                                 (mailto:Mark.Eccleston@valirx.com)

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz

 

 

Notes for Editors

 

About ValiRx

 

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

 

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

 

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

 

For further information, visit: www.valirx.com (http://www.valirx.com/)

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGEASAEFEELFFA